A medical oncologist at an integrated health network on the East Coast expects the health care industry to adopt both MRD and ctDNA monitoring in the near future. They currently use these technologies for NSCLC, CRC, and breast cancer, with some monitoring done for melanoma patients as well. Monitoring to inform maintenance therapy is a use case they have adopted. They imagine that other cancer types would benefit from these tests, including renal cancer, bladder cancers, and even some rare tumor types like tumors of the head and neck. They utilize Natera and Guardant and are satisfied with both vendors. They do not expect to change vendors anytime soon, and they also do not imagine that the MRD marketplace will be a “winner takes all” landscape. Customer service was cited as key vendor criteria, and care needs to be taken so test costs do not fall on patients.

Campaign Details

MRD Ad Board

DeciBio conducted ~11 interviews with medical oncologists and biopharma executives to understand how minimal residual disease (MRD) testing and ctDNA monitoring are currently integrated into solid tumor care